The suppressive effects of type I IFNs on tumor growth have led to investigations of the use of IFN-α/−β for augmenting the treatment of various cancers, including colon cancer, HCC, leukemia, and melanoma [11, 12, 44, 100-103], with some benefits reported. This evidence concerns the gene IFNA1 and cancer.